Replies to post #360964 on Anavex Life Sciences Corp (AVXL)

[B60611]

No, it’s the drug. Missling’s “direction” has chopped 35% off the SP nearly 7 years after the Nasdaq uplisting, in spite of the drug’s remarkable successes. Meanwhile, he has enriched himself with 4 million or so option awards in that same time frame. Funny how that worked.